These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 2607817)

  • 1. [Neoplasms associated with chronic lymphatic leukemia. Incidence and characteristics in a series of 232 patients].
    López-Guillermo A; Reverter JC; Cervantes F; Viñolas N; Rovira M; Urbano-Ispizua A; Montserrat E; Rozman C
    Med Clin (Barc); 1989 Dec; 93(18):681-3. PubMed ID: 2607817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What is changing in the natural history of chronic lymphocytic leukemia?
    Molica S; Levato D
    Haematologica; 2001 Jan; 86(1):8-12. PubMed ID: 11146563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical and laboratory prognostic parameters for leukemic types of chronic lymphoproliferative diseases].
    Kardum-Skelin I; Planinc-Peraica A; Ostojić Kolonić S; Radić-Kristo D; Milas M; Vrhovac R; Sustercić D; Minigo H; Jaksić B
    Acta Med Croatica; 2008 Oct; 62(4):351-64. PubMed ID: 19205412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical course of lung carcinoma in patients with chronic lymphocytic leukemia.
    Parekh K; Rusch V; Kris M
    Cancer; 1999 Nov; 86(9):1720-3. PubMed ID: 10547544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural history of early chronic lymphocytic leukemia. A single institution study with emphasis on the impact of disease-progression on overall survival.
    Molica S; Levato D; Dattilo A
    Haematologica; 1999 Dec; 84(12):1094-9. PubMed ID: 10586211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary malignant tumors (lymphoma excluded) in patients with chronic lymphocytic leukemia. A series of 22 cases from a retrospective study of 248 patients.
    Lauvin R; Le Breton-Kashi Y; Jego P; Grosbois B; Leblay R
    Ann Med Interne (Paris); 1996; 147(6):389-92. PubMed ID: 9092340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia.
    Maddocks-Christianson K; Slager SL; Zent CS; Reinalda M; Call TG; Habermann TM; Bowen DA; Hoyer JD; Schwager S; Jelinek DF; Kay NE; Shanafelt TD
    Br J Haematol; 2007 Nov; 139(3):398-404. PubMed ID: 17910629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Second neoplasms in chronic lymphocytic leukemia: analysis of incidence as a function of the length of follow-up.
    Molica S; Alberti A
    Haematologica; 1989; 74(5):481-5. PubMed ID: 2511118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The American College of Surgeons Commission on Cancer and the American Cancer Society. The National Cancer Data Base report on age, gender, treatment, and outcomes of patients with chronic lymphocytic leukemia.
    Diehl LF; Karnell LH; Menck HR
    Cancer; 1999 Dec; 86(12):2684-92. PubMed ID: 10594864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I/II study examining pentostatin, chlorambucil, and theophylline in patients with relapsed chronic lymphocytic leukemia and non-Hodgkin's lymphoma.
    Willis CR; Goodrich A; Park K; Waselenko JK; Lucas M; Reese A; Diehl LF; Grever MR; Byrd JC; Flinn IW
    Ann Hematol; 2006 May; 85(5):301-7. PubMed ID: 16518606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum insulin-like growth factor is not elevated in patients with early B-cell chronic lymphocytic leukemia but is still a prognostic factor for disease progression.
    Molica S; Vitelli G; Mirabelli R; Digiesu G; Giannarelli D; Cuneo A; Ribatti D; Vacca A
    Eur J Haematol; 2006 Jan; 76(1):51-7. PubMed ID: 16343271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High dose chlorambucil versus Binet's modified cyclophosphamide, doxorubicin, vincristine, and prednisone regimen in the treatment of patients with advanced B-cell chronic lymphocytic leukemia. Results of an international multicenter randomized trial. International Society for Chemo-Immunotherapy, Vienna.
    Jaksic B; Brugiatelli M; Krc I; Losonczi H; Holowiecki J; Planinc-Peraica A; Kusec R; Morabito F; Iacopino P; Lutz D
    Cancer; 1997 Jun; 79(11):2107-14. PubMed ID: 9179056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunocytochemical detection of bcl-2 and p53 proteins in B-chronic lymphocytic leukemia patients.
    Klobusická M; Kusenda J; Babusíková O
    Neoplasma; 2002; 49(6):387-93. PubMed ID: 12584586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.
    O'Brien S; Moore JO; Boyd TE; Larratt LM; Skotnicki A; Koziner B; Chanan-Khan AA; Seymour JF; Bociek RG; Pavletic S; Rai KR
    J Clin Oncol; 2007 Mar; 25(9):1114-20. PubMed ID: 17296974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population.
    Perkins JG; Flynn JM; Howard RS; Byrd JC
    Cancer; 2002 Apr; 94(7):2033-9. PubMed ID: 11932906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of lymphocyte morphology in patients with advanced chronic lymphocytic leukemia treated with first line therapy of fludarabine + prednisone.
    Mauro FR; Gentile M; Mancini F; Giannarelli D; Guarini A; De Propriis MS; Cerretti R; Foa R
    Haematologica; 2002 Jun; 87(6):602-8. PubMed ID: 12031916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD38 expression in B-chronic lymphocytic leukemia: association with clinical presentation and outcome in 155 patients.
    Domingo-Domènech E; Domingo-Clarós A; Gonzàlez-Barca E; Beneitez D; Alonso E; Romagosa V; De Sanjos S; Petit J; Grañena A; Fernández de Sevilla A
    Haematologica; 2002 Oct; 87(10):1021-7. PubMed ID: 12368155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CHOP versus prednisolone + chlorambucil in chronic lymphocytic leukemia (CLL): preliminary results of a randomized multicenter study.
    Hansen MM; Andersen E; Christensen BE; Christiansen I; Geisler C; Kristensen D; Jensen KB; Junker P
    Nouv Rev Fr Hematol (1978); 1988; 30(5-6):433-6. PubMed ID: 3065739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response to fludarabine in B-cell chronic lymphocytic leukemia patients previously treated with chlorambucil as up-front therapy and a CHOP-like regimen as second line therapy.
    Liso V; Molica S; Capalbo S; Pogliani E; Battista C; Broccia G; Montillo M; Cuneo A; Leoni P; Specchia G; Castoldi G
    Haematologica; 2001 Nov; 86(11):1165-71. PubMed ID: 11694402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hodgkin transformation of chronic lymphocytic leukemia: the M. D. Anderson Cancer Center experience.
    Tsimberidou AM; O'Brien S; Kantarjian HM; Koller C; Hagemeister FB; Fayad L; Lerner S; Bueso-Ramos CE; Keating MJ
    Cancer; 2006 Sep; 107(6):1294-302. PubMed ID: 16902984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.